ArticleTherapeutic advances in medical oncology2025
Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring.The journal of liquid biopsy · 2026Article
- Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating tumor DNA (ctDNA) analysis that is tumor-informed and personalized requires high-quality tissue specimens, which are unavailable in certain clinical contexts and pathology practice in Southeast Asia. Objectives: We aimed to develop and clinically validate an alternative tumor-naïve ctDNA assay. Design: A retrospective observational study. Methods: Our tumor-naïve multimodal profiling integrated mutation detection, using both amplicon and hybridization sequencing, with analysis of copy number alteration (CNA) and fragmentomics of cfDNA. We analyzed blood samples of 948 cancer patients and 566 non-cancer donors enrolled in previous studies to evaluate the analytical performance of ctDNA detection. Clinical performance was assessed using post-surgical samples of 97 breast cancer and 51 colorectal cancer patients to compare tumor-naïve ctDNA status with clinical recurrence. The performance was directly compared with the tumor-informed method using identical samples. Results: For mutations, a combination of amplicon and hybridization sequencing provided higher sensitivity and broader coverage of mutation detection than single methods. Variants of clonal hematopoiesis of intermediate potential were common, mainly in the Conclusion: The tumor-naïve method could be a reliable alternative to monitor ctDNA when obtaining high-quality tissue samples is challenging. The performance of this method was better in high ctDNA-shedding cancer or at the metastatic stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.